Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer - PubMed (original) (raw)
Clinical Trial
. 2008 Mar 1;26(7):1135-41.
doi: 10.1200/JCO.2007.14.3685.
Affiliations
- PMID: 18309949
- DOI: 10.1200/JCO.2007.14.3685
Clinical Trial
Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer
Yun Oh et al. J Clin Oncol. 2008.
Abstract
Purpose: Enzastaurin, an oral serine/threonine kinase inhibitor, suppresses protein kinase C (PKC) and protein kinase B/AK transforming (AKT) signaling, induces tumor cell apoptosis, and inhibits proliferation and angiogenesis. Increased PKC and AKT activity is associated with poor prognosis in non-small-cell lung cancer (NSCLC). This phase II trial of enzastaurin was conducted to determine the 6-month progression-free survival (PFS) rate in advanced, metastatic NSCLC.
Patients and methods: Patients with metastatic (stage IV and wet IIIB) NSCLC, Eastern Cooperative Oncology Group performance status <or= 2, and <or= two prior systemic regimens (including one or more platinum-based chemotherapy regimens) received 500 mg of enzastaurin administered once daily.
Results: Fifty-five patients were enrolled (55% male patients, 45% female patients; median age, 63 years; range, 44 to 82 years; 78% of patients having stage IV disease). Adenocarcinoma was the most common diagnosis (65%). Prior therapies included radiotherapy (73%) and epidermal growth factor inhibitors (29%). Median PFS was 1.8 months (95% CI, 1.7 to 1.9). Six-month PFS rate was 13% (95% CI, 3.9% to 21.5%). Median overall survival (OS) was 8.4 months (95% CI, 6.0 to 13.6 months). The 12-month OS rate was 44% (95% CI, 30.5% to 57.3%). Nineteen patients (35%) had stable disease. No objective responses were observed. Seven patients (13%) had PFS >or= 6 months, three of whom continued for more than 10 months. The most common toxicity was fatigue (grade <or= 3; n = 17). Grade 3 or worse toxicities were fatigue (n = 2), thromboembolism (n = 1), ataxia (n = 1), and anemia (n = 1). Two patients discontinued treatment because of drug-related fatigue and dizziness. Five patients died while enrolled in the study (non drug-related).
Conclusion: Although the primary end point of a 20% PFS rate was not achieved, 13% of the patients had PFS for >or= 6 months. Given the tolerability and survival data, evaluation of enzastaurin in combination with cytotoxic drugs is warranted in NSCLC.
Similar articles
- Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
Schiller JH, Larson T, Ou SH, Limentani S, Sandler A, Vokes E, Kim S, Liau K, Bycott P, Olszanski AJ, von Pawel J. Schiller JH, et al. J Clin Oncol. 2009 Aug 10;27(23):3836-41. doi: 10.1200/JCO.2008.20.8355. Epub 2009 Jul 13. J Clin Oncol. 2009. PMID: 19597027 Clinical Trial. - Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.
Robertson MJ, Kahl BS, Vose JM, de Vos S, Laughlin M, Flynn PJ, Rowland K, Cruz JC, Goldberg SL, Musib L, Darstein C, Enas N, Kutok JL, Aster JC, Neuberg D, Savage KJ, LaCasce A, Thornton D, Slapak CA, Shipp MA. Robertson MJ, et al. J Clin Oncol. 2007 May 1;25(13):1741-6. doi: 10.1200/JCO.2006.09.3146. Epub 2007 Mar 26. J Clin Oncol. 2007. PMID: 17389337 Clinical Trial. - Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
Blumenschein GR Jr, Gatzemeier U, Fossella F, Stewart DJ, Cupit L, Cihon F, O'Leary J, Reck M. Blumenschein GR Jr, et al. J Clin Oncol. 2009 Sep 10;27(26):4274-80. doi: 10.1200/JCO.2009.22.0541. Epub 2009 Aug 3. J Clin Oncol. 2009. PMID: 19652055 Clinical Trial. - Enzastaurin, a protein kinase Cbeta- selective inhibitor, and its potential application as an anticancer agent in lung cancer.
Herbst RS, Oh Y, Wagle A, Lahn M. Herbst RS, et al. Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4641-6. doi: 10.1158/1078-0432.CCR-07-0538. Clin Cancer Res. 2007. PMID: 17671157 Review. - Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion.
Bunn PA Jr, Thatcher N. Bunn PA Jr, et al. Oncologist. 2008;13 Suppl 1:37-46. doi: 10.1634/theoncologist.13-S1-37. Oncologist. 2008. PMID: 18263773 Review.
Cited by
- An Update on Protein Kinases as Therapeutic Targets-Part I: Protein Kinase C Activation and Its Role in Cancer and Cardiovascular Diseases.
Silnitsky S, Rubin SJS, Zerihun M, Qvit N. Silnitsky S, et al. Int J Mol Sci. 2023 Dec 18;24(24):17600. doi: 10.3390/ijms242417600. Int J Mol Sci. 2023. PMID: 38139428 Free PMC article. Review. - Protein Kinase C as a Therapeutic Target in Non-Small Cell Lung Cancer.
Sadeghi MM, Salama MF, Hannun YA. Sadeghi MM, et al. Int J Mol Sci. 2021 May 24;22(11):5527. doi: 10.3390/ijms22115527. Int J Mol Sci. 2021. PMID: 34073823 Free PMC article. Review. - A new indolocarbazole derivative in melanoma and carcinoma lung in vivo treatment.
Lantsova A, Golubeva I, Borisova L, Nikolaeva L, Ektova L, Dmitrieva M, Orlova O. Lantsova A, et al. BMC Complement Med Ther. 2021 Apr 10;21(1):117. doi: 10.1186/s12906-021-03294-2. BMC Complement Med Ther. 2021. PMID: 33838683 Free PMC article. - Synthesis and Biological Evaluation of Novel 4-(4-Formamidophenylamino)-_N_-methylpicolinamide Derivatives as Potential Antitumor Agents.
Meng N, Zhou S, Hu M, Xu Y, Xia Y, Zeng X, Yu L. Meng N, et al. Molecules. 2021 Feb 21;26(4):1150. doi: 10.3390/molecules26041150. Molecules. 2021. PMID: 33670007 Free PMC article. - Molecular mechanism underlying the pharmacological interactions of the protein kinase C-β inhibitor enzastaurin and erlotinib in non-small cell lung cancer cells.
Steen NV, Potze L, Giovannetti E, Cavazzoni A, Ruijtenbeek R, Rolfo C, Pauwels P, Peters GJ. Steen NV, et al. Am J Cancer Res. 2017 Apr 1;7(4):816-830. eCollection 2017. Am J Cancer Res. 2017. PMID: 28469955 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical